AngioDynamics Inc. (ANGO) Releases Q4 Earnings Guidance
AngioDynamics Inc. (NASDAQ:ANGO) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.18-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.21, Stock Ratings Network.com reports. The company issued revenue guidance of $91-95 million, compared to the consensus revenue estimate of $93.17 million.
ANGO has been the subject of a number of recent research reports. Analysts at Raymond James upgraded shares of AngioDynamics from a market perform rating to an outperform rating in a research note on Wednesday, March 12th. They now have a $19.00 price target on the stock. Analysts at Zacks reiterated a neutral rating on shares of AngioDynamics in a research note on Friday, January 10th. They now have a $19.00 price target on the stock.
AngioDynamics Inc. (NASDAQ:ANGO) traded up 3.39% on Wednesday, hitting $15.85. 245,001 shares of the company’s stock traded hands. AngioDynamics Inc. has a one year low of $9.52 and a one year high of $19.00. The stock’s 50-day moving average is $15.93 and its 200-day moving average is $15.7. The company’s market cap is $557.3 million.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, April 9th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.07. The company had revenue of $88.20 million for the quarter, compared to the consensus estimate of $86.85 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. On average, analysts predict that AngioDynamics Inc. will post $0.33 earnings per share for the current fiscal year.
AngioDynamics, Inc designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.